Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving Doxorubicin and cyclophosphamide

Breast Journal

Volumn 17, Issue 5, 2011, Pages 536-538

  Wessels, Alette M ^a   Flockhart, David A ^a   Carpenter, Janet S ^b   Radovich, Milan ^c   Li, Lang ^a   Miller, Kathy D ^c   Sledge, George W ^c   Storniolo, Anna M ^c   Otte, Julie L ^c   Lemler, Suzanne M ^a   Schneider, Bryan P ^a,c  

^a WISHARD MEMORIAL HOSPITAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; DOXORUBICIN;

ADULT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; PREMATURE OVARIAN FAILURE; PREMENOPAUSE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGE FACTORS; AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DOXORUBICIN; FEMALE; GENE FREQUENCY; HUMANS; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY OVARIAN INSUFFICIENCY; YOUNG ADULT;

EID: 81155160863     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2011.01144.x     Document Type: Letter

References (18)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-83. (Pubitemid 46594124)
3. Bines J, Oleske DM, Cobleigh MA,. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-29. (Pubitemid 26134232)
4. Del Mastro L, Venturini M, Sertoli MR, Rosso R,. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997; 43: 183-90. (Pubitemid 27165879)
5. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N,. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999; 17: 2365-70. (Pubitemid 29368234)
6. Walshe JM, Denduluri N, Swain SM,. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006; 24: 5769-79. (Pubitemid 46646480)
7. Rubens RD, Hayward JL, Knight RK, et al. Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet 1983; 1: 839-43. (Pubitemid 13165290)
8. Goldhirsch A, Gelber RD, Castiglione M,. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1990; 1: 183-8. (Pubitemid 20218533)
9. de Bruin JP, Bovenhuis H, van Noord PA, et al. The role of genetic factors in age at natural menopause. Hum Reprod 2001; 16: 2014-8. (Pubitemid 32916239)
10. Colvin M, Padgett CA, Fenselau C,. A biologically active metabolite of cyclophosphamide. Cancer Res 1973; 33: 915-8.
11. Chang TK, Weber GF, Crespi CL, Waxman DJ,. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-37. (Pubitemid 23360263)
12. Roy P, Yu LJ, Crespi CL, Waxman DJ,. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999; 27: 655-66. (Pubitemid 29252439)
13. Carpenter JS, Andrykowski MA, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer 1998; 82: 1682-91. (Pubitemid 28208918)
14. Carpenter JS, Johnson D, Wagner L, Andrykowski M,. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 2002; 29: E16-25.
15. Taffe J, Dennerstein L,. Menstrual diary data and menopausal transition: methodologic issues. Acta Obstet Gynecol Scand 2002; 81: 588-94. (Pubitemid 34827868)
16. Lee S, Kil WJ, Chun M, et al. Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause 2009; 16: 98-103.
17. Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50: 2202-10. (Pubitemid 38924398)
18. Su HI, Sammel MD, Velders L, et al. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil Steril 2010; 94: 645-54.